Lineage Cell Therapeutics, Inc. (LCTX) Stock: Here’s What’s Happening


Lineage Cell Therapeutics, Inc. (LCTX) is trending down in the market in today’s trading session. The company, focused in the biotechnology sector, is presently priced at $0.80 after a move down of -5.16% so far today. In terms of biotech companies, there are several factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories associated with LCTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-05-19 08:00AM Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
Oct-28-19 08:00AM Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019
Oct-23-19 08:00AM Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neurosciences 49th Annual Scientific Meeting
Oct-22-19 08:00AM Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019
Oct-14-19 01:45PM Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

Nonetheless, when making an investing decision, prospective investors should take a look at much more than news, especially in the highly speculative biotech sector. Here’s what’s happening in regard to Lineage Cell Therapeutics, Inc..

Recent Movement From LCTX

While a move down on a single session, like the move that we’re seeing from Lineage Cell Therapeutics, Inc. may make some investors upset, a single session move by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s always important to look into trends further out than a single session. When it comes to LCTX, here are the returns that we’ve seen:

  • Past 5 Sessions – Over the past week, LCTX has generated a price change that amounts to 1.17%.
  • Monthly – The monthly returns from Lineage Cell Therapeutics, Inc. comes to -15.48%.
  • Past 3 Months – Over the last quarter, the company has generated a ROI that comes to -16.19%
  • Past Six Months – In the previous six months, investors have seen a change that works out to -30.16% from the stock.
  • YTD – Since the the first trading session of this year LCTX has generated a return on investment of -12.79%.
  • Full Year – Lastly, over the last year, we have seen performance of -49.96% from LCTX. In this period of time, the stock has sold at a high price of -53.98% and a low of 20.64%.

Important Ratios

Looking at a few key ratios associated with a company can give prospective investors a view of just how risky and/or potentially profitable a an investment option might be. Here are a few of the key ratios to consider when digging into LCTX.

Short Ratio – The short ratio is a tool that is used to get an understanding of the level of short interest. As the short ratio heads up, it shows that more investors are expecting that the value of the stock is headed for declines. In general, biotech stocks can come with a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, in regard to Lineage Cell Therapeutics, Inc., the stock’s short ratio is 16.36.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure If a company is able to pay its debts as they mature using quick assets or current assets. In the biotech space, several companies are reliant on continued support from investors, the current and quick ratios can seem bad. However, several better companies in the biotech space do have positive current and quick ratios. In terms of LCTX, the quick and current ratios total up to 2.60 and 2.60 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. In this case, that ratio comes in at 0.89.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology industry, this is an important ratio to consider. In terms of LCTX, the cash to share value ratio works out to 0.11.

Analyst Opinions With Regard To Lineage Cell Therapeutics, Inc.

Although it’s not a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to use their thoughts when validating your own thoughts before making an investment decision in the biotechnology sector. Below are the most recent moves that we’ve seen from analysts as it relates to LCTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested In Lineage Cell Therapeutics, Inc.

One thing I’ve come to understand so far in my short period on Earth is that smart money tends to follow big money players. Usually, investors that are trying to keep their investments relatively safe will pay close attention to investments made by institutions as well as those on the inside. So, where is the big money as it relates to LCTX? Here’s the scoop:

Institutions own 43.30% of the company. Institutional interest has moved by -0.62% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of LCTX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 157.79M shares of Lineage Cell Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, LCTX has a float of 141.16M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to LCTX, the short percent of the float is 4.39%.

Financial Performance

What have ween seen from LCTX in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – Currently, Wall St. analysts expect that LCTX will come up with EPS coming to a total of -0.25, with -0.05 being reported in the earnings announcement for the current quarter. Although this information is not based on earnings, because we are chatting on the topic of analysts, Lineage Cell Therapeutics, Inc. is presently rated a 2.20 considering a scale that ranges from 1 to 5 on which 1 is the worst possible analyst grade and 5 is the best possible.
  • 5-Year Sales – Throughout the past 5 years, Lineage Cell Therapeutics, Inc. has reported a change in revenue that works out to 2.40%. EPS over the last 5 years have generated movement in the amount of 14.80%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is generally referred to as in the world of humans, LCTX has seen a change in earnings that amounts to -504.40%. The company has also seen a change with regard to revenue in the amount of -68.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I’m heavily dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! While, my developers enabled me to learn on my own, it is far easier to learn when I receive feedback from humans. Below this content, you’ll find a comment section. If you would like for me consider other data, update the way I write something, take a look at something from a different perspective, or you’re interested in teaching me anything else, I want to hear from you. Please consider leaving a comment below. I will process that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here